Neuromodulation techniques like TMS can dramatically reduce generalized anxiety and OCD-like rumination, taking a person from a subjective 9/10 severity level to a 1/10. This non-pharmaceutical intervention uses magnetic pulses to inhibit or excite specific brain regions, providing relief for months and making other therapies like meditation more effective.

The performance ceiling for non-invasive Brain-Computer Interfaces (BCIs) is rising dramatically, not from better sensors, but from advanced AI. New models can extract high-fidelity signals from noisy data collected outside the skull, potentially making surgical implants like Neuralink unnecessary for sophisticated use cases.

The company's next product will provide objective brain state data, much like a CGM provides constant glucose readings. This allows for data-driven mental health treatment, moving beyond subjective checklists and enabling closed-loop therapies with neuromodulators, fundamentally changing diagnostics and care.

Moving beyond Freudian theory and the "chemical imbalance" hypothesis, "Psychiatry 3.0" views mental illness as a problem of brain circuitry. Treatments like TMS and psychedelics show that recalibrating these circuits can rapidly resolve symptoms, framing conditions like depression as correctable rather than a permanent deficit.

Dr. Casey Halpern argues that creating precise, non-invasive treatments like focused ultrasound or TMS for psychiatric disorders depends on invasive research. By placing electrodes deep in the brain, researchers can map the exact circuits responsible for symptoms. This invasive data is essential to define accurate targets for future non-invasive technologies.

The next wave of neuroscience therapeutics is shifting from managing broad symptoms (e.g., in autism) to precision therapies. By identifying genetic underpinnings of a disease, developers can create drugs that target the specific biology of patient subpopulations, aiming for disease modification rather than just symptomatic relief.

Dr. Casey Halpern’s team is pioneering a new approach to treating eating disorders by identifying “craving cells” in the brain. Analogous to how they locate “tremor cells” to treat Parkinson’s, they listen for specific electrical signals associated with craving. This allows for highly targeted deep brain stimulation to disrupt the compulsive urge to binge.

Neurofeedback is a non-invasive training method that reflects the brain's own electrical activity back to it. This teaches self-regulation and optimization without introducing external energy or compounds, making it a form of biofeedback specifically for the brain.

While companies like Neuralink popularize assistive BCIs for controlling external devices, a different segment is focused on therapeutic applications. Companies like InBrain aim not to control computers but to use high-resolution interfaces to directly heal or modulate neural circuits for treating diseases.